Succinic Acid

Succinic Acid

SCHEMBL507717

Clc1ccc2c(c1NCc1ccc3nc(C4CCCCC4)sc3c1)CCNCC2.O=C(O)CCC(=O)O

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4

The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 5/20 0.37
CSF1R P07333 2/20 0.35
HSD17B10 Q99714 2/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
AURKB Q96GD4 1/20 0.33
PDE5A O76074 2/20 0.33
UBE2M P61081 1/20 0.33
DCUN1D1 Q96GG9 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
TP53 P04637 1/20 0.32
LMNA P02545 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PPARD Q03181 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10228316 0.94 CSF1R (0.38) P2RX3CSF1RHSD17B10NPC1RAB9A
Succinic Acid SCHEMBL507736 0.84 SMN1; SMN2 (0.40) HSD17B10NPC1RAB9AMEN1KMT2A
Succinic Acid SCHEMBL4248115 0.83 HTR2B (0.37) HSD17B10PDE5ASMN1; SMN2
SCHEMBL507473 0.80 UBE2M (0.37) P2RX3CSF1RPDE5AUBE2MDCUN1D1
Hydrochloric Acid SCHEMBL507272 0.80 CSF1R (0.37) CSF1RHSD17B10AURKBPDE5A
Succinic Acid SCHEMBL507541 0.78 SRD5A2 (0.35) MEN1KMT2ASMN1; SMN2
Succinic Acid SCHEMBL506560 0.78 FFAR1 (0.35) PDE5A
Succinic Acid SCHEMBL2588679 0.78 HDAC1 (0.40) MEN1KMT2ASMN1; SMN2
Succinic Acid SCHEMBL507443 0.78 HTR2B (0.36) NPC1RAB9AMEN1KMT2A
Succinic Acid SCHEMBL508455 0.77 HCAR3 (0.38) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720836-B1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS LILLY CO ELI (US) 2014-04-16 EP disclosed
US-8580780-B2 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist ELI LILLY AND COMPANY (US) 2013-11-12 US disclosed
EP-2479168-A1 6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo [d]Azepines as 5-HT2C Receptor Agonists ELI LILLY AND COMPANY (US) 2012-07-25 EP disclosed
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist ELI LILLY AND COMPANY (US) 2012-02-02 US disclosed
US-8022062-B2 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists ELI LILLY AND COMPANY (US) 2011-09-20 US disclosed
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ARRAY BIOPHARMA, INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS HTR2C, HTR5A, HTR4 P2RX3 417/4885CSF1R 1301/4885HSD17B10 699/4885
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist HTR2C, HTR4, HTR1A P2RX3 275/4885CSF1R 1812/4885HSD17B10 1875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.